Clinical Trial-based Evidence of Benefit Research has shown that GLP-1R agonists play a significant role in reducing the likelihood of MACE, such as MI, cardiovascular death, and stroke [102]
Why Compounded GLP-1 Programs Exist (Supply, Cost, and Access Factors) If you are new to this space, a reasonable question is: why do compounded versions of these medications exist at all when FDA-approved versions are available
Usually, this tiredness is transient and improves by the second or third week as your metabolism stabilizes and you become more adept at fueling your body within the new parameters of the medication

Red flag symptoms requiring urgent medical attention include: Severe, persistent abdominal pain , particularly in the upper abdomen or epigastric region, which could indicate pancreatitis (a rare but serious adverse effect of GLP-1 therapy) Difficulty swallowing (dysphagia) or painful swallowing (odynophagia) Unintentional weight loss beyond expected therapeutic effects Persistent vomiting that prevents adequate oral intake or medication administration Right upper quadrant pain, fever, or yellowing of skin/eyes , which could indicate gallbladder disease (a known risk with weight loss on GLP-1 therapies) Symptoms of gastroparesis such as early satiety, postprandial fullness, or vomiting undigested food Call 911 or seek emergency care immediately for: Severe chest pain that could represent cardiac pathology rather than reflux Evidence of gastrointestinal bleeding , including black, tarry stools or vomiting blood or coffee-ground material If you suspect pancreatitis (persistent severe abdominal pain, sometimes radiating to the back, with or without nausea/vomiting), stop taking the GLP-1 medication immediately and seek urgent medical care, as directed in FDA prescribing information

Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action